ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $18,669.75 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,095 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total value of $18,669.75. Following the completion of the transaction, the insider now owns 21,275 shares of the company’s stock, valued at approximately $362,738.75. The trade was a 4.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

James Kihara also recently made the following trade(s):

• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $19.96, for a total value of $9,481.00.

ACADIA Pharmaceuticals Trading Down 0.5 %

NASDAQ:ACAD traded down $0.08 during mid-day trading on Wednesday, reaching $17.03. 902,668 shares of the stock were exchanged, compared to its average volume of 1,762,028. The business has a fifty day moving average price of $18.35 and a 200 day moving average price of $17.02. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $20.68. The firm has a market capitalization of $2.84 billion, a PE ratio of 21.83 and a beta of 0.43.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 8th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $20.00 price objective on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price for the company. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.93.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several hedge funds have recently made changes to their positions in ACAD. Virtus Fund Advisers LLC acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at approximately $39,000. R Squared Ltd bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $47,000. Quest Partners LLC lifted its position in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth $64,000. Finally, KBC Group NV grew its holdings in shares of ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 2,044 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.